Canakinumab treatment in children with familial Mediterranean fever: report from a single center

Yazilitas F., Aydog O., ÖZLÜ S. G., Cakici E. K., Gungor T., Eroglu F. K., ...Daha Fazla

RHEUMATOLOGY INTERNATIONAL, cilt.38, sa.5, ss.879-885, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 5
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1007/s00296-018-3993-5
  • Dergi Adı: RHEUMATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.879-885
  • Anahtar Kelimeler: Amyloidosis, Canakinumab, Childhood, Familial Mediterranean fever, Uveitis, AUTOINFLAMMATORY DISEASES, SECONDARY AMYLOIDOSIS, CASE SERIES, COLCHICINE, INTERLEUKIN-1, THERAPY, UVEITIS, PATIENT, CHILDHOOD, ANAKINRA
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5-10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.